NASDAQ:ANCN - ANCHIANO THERAP/S Stock Price, Forecast & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding ANCHIANO THERAP/S Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $1.38 +0.02 (+1.47 %) (As of 02/21/2020 04:00 PM ET) Add Compare Today's Range$1.33Now: $1.38▼$1.4050-Day Range$1.28MA: $1.39▼$1.6052-Week Range$1.04Now: $1.38▼$9.25Volume19,931 shsAverage Volume25,131 shsMarket Capitalization$10.24 millionP/E RatioN/ADividend YieldN/ABetaN/A ProfileAnalyst RatingsAdvanced ChartEarningsInstitutional OwnershipHeadlinesSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email Anchiano Therapeutics Ltd, a clinical-stage biotechnology company, develops gene therapies to treat early-stage bladder cancer. It is primarily developing Inodiftagene that is in various clinical trials for the treatment of non-muscle-invasive bladder cancer. The company was formerly known as BioCancell Ltd. and changed its name Anchiano Therapeutics Ltd in July 2018. The company was founded in 2004 and is headquartered in Jerusalem, Israel. Industry, Sector and Symbol Stock Exchange NASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:ANCN Previous Symbol CUSIPN/A CIKN/A Webhttp://www.anchiano.com/ Phone972-2548-6555Debt Debt-to-Equity Ratio0.11 Current Ratio1.60 Quick Ratio1.60Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AProfitability EPS (Most Recent Fiscal Year)($5.25) Net Income$-13,280,000.00 Net MarginsN/A Return on Equity-255.67% Return on Assets-136.55%Miscellaneous Employees19 Outstanding Shares7,420,000Market Cap$10.24 million Next Earnings Date3/23/2020 (Estimated) OptionableNot Optionable Receive ANCN News and Ratings via Email Sign-up to receive the latest news and ratings for ANCN and its competitors with MarketBeat's FREE daily newsletter. NASDAQ:ANCN Rates by TradingView ANCHIANO THERAP/S (NASDAQ:ANCN) Frequently Asked Questions What is ANCHIANO THERAP/S's stock symbol? ANCHIANO THERAP/S trades on the NASDAQ under the ticker symbol "ANCN." How were ANCHIANO THERAP/S's earnings last quarter? ANCHIANO THERAP/S (NASDAQ:ANCN) announced its quarterly earnings data on Monday, August, 5th. The company reported ($0.05) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.17) by $0.12. View ANCHIANO THERAP/S's Earnings History. When is ANCHIANO THERAP/S's next earnings date? ANCHIANO THERAP/S is scheduled to release their next quarterly earnings announcement on Monday, March 23rd 2020. View Earnings Estimates for ANCHIANO THERAP/S. What price target have analysts set for ANCN? 3 Wall Street analysts have issued twelve-month price targets for ANCHIANO THERAP/S's shares. Their forecasts range from $12.00 to $16.00. On average, they anticipate ANCHIANO THERAP/S's stock price to reach $14.00 in the next twelve months. This suggests a possible upside of 914.6% from the stock's current price. View Analyst Price Targets for ANCHIANO THERAP/S. What is the consensus analysts' recommendation for ANCHIANO THERAP/S? 3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for ANCHIANO THERAP/S in the last year. There are currently 3 hold ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for ANCHIANO THERAP/S. Has ANCHIANO THERAP/S been receiving favorable news coverage? News coverage about ANCN stock has been trending very negative on Friday, InfoTrie Sentiment Analysis reports. The research group identifies positive and negative news coverage by monitoring more than six thousand news and blog sources in real-time. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores closest to five being the most favorable. ANCHIANO THERAP/S earned a news sentiment score of -3.0 on InfoTrie's scale. They also assigned press coverage about the company a news buzz of 0.0 out of 10, indicating that recent news coverage is extremely unlikely to have an impact on the stock's share price in the immediate future. View News Stories for ANCHIANO THERAP/S. Who are some of ANCHIANO THERAP/S's key competitors? Some companies that are related to ANCHIANO THERAP/S include Iterum Therapeutics (ITRM), Humanigen (HGEN), Annovis Bio (ANVS), Jaguar Health (JAGX), Bellerophon Therapeutics (BLPH), Evoke Pharma (EVOK), Moleculin Biotech (MBRX), RegeneRx Biopharmaceuticals (RGRX), Vistagen Therapeutics (VTGN), Alimera Sciences (ALIM), Generex Biotechnology (GNBT), Edesa Biotech (EDSA), Addex Therapeutics (ADDXF), Pulmatrix (PULM) and Akari Therapeutics (AKTX). What other stocks do shareholders of ANCHIANO THERAP/S own? Based on aggregate information from My MarketBeat watchlists, some companies that other ANCHIANO THERAP/S investors own include Acasti Pharma (ACST), Allena Pharmaceuticals (ALNA), Cronos Group (CRON), CytomX Therapeutics (CTMX), Gilead Sciences (GILD), Huntington Bancshares (HBAN), Kiniksa Pharmaceuticals (KNSA), Methanex (MEOH), PacWest Bancorp (PACW) and People's United Financial (PBCT). Who are ANCHIANO THERAP/S's key executives? ANCHIANO THERAP/S's management team includes the folowing people: Dr. Frank G. Haluska, Pres, CEO & Director (Age 60)Mr. Jonathan Burgin, CFO & COO (Age 58)Mr. Ronald K. Knickerbocker, Sr. VP of Clinical Devel. & Data Sciences (Age 53)Prof. Abraham Hochberg, Co-Founder & Chief Scientific Officer (Age 81)Dr. Michal Gilon Ohev-Zion, VP of R&D (Age 41) When did ANCHIANO THERAP/S IPO? (ANCN) raised $35 million in an IPO on Tuesday, February 12th 2019. The company issued 2,400,000 shares at $14.55 per share. Oppenheimer acted as the underwriter for the IPO and Ladenburg Thalmann was co-manager. Who are ANCHIANO THERAP/S's major shareholders? ANCHIANO THERAP/S's stock is owned by a number of of institutional and retail investors. Top institutional investors include Meitav Dash Investments Ltd. (5.01%). Which institutional investors are selling ANCHIANO THERAP/S stock? ANCN stock was sold by a variety of institutional investors in the last quarter, including Meitav Dash Investments Ltd.. How do I buy shares of ANCHIANO THERAP/S? Shares of ANCN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab. What is ANCHIANO THERAP/S's stock price today? One share of ANCN stock can currently be purchased for approximately $1.38. How big of a company is ANCHIANO THERAP/S? ANCHIANO THERAP/S has a market capitalization of $10.24 million. The company earns $-13,280,000.00 in net income (profit) each year or ($5.25) on an earnings per share basis. ANCHIANO THERAP/S employs 19 workers across the globe.View Additional Information About ANCHIANO THERAP/S. What is ANCHIANO THERAP/S's official website? The official website for ANCHIANO THERAP/S is http://www.anchiano.com/. How can I contact ANCHIANO THERAP/S? ANCHIANO THERAP/S's mailing address is 1/3 HIGH-TECH VILLAGE GIVAT RAM P.0. BOX 39264, JERUSALEM L3, 9139102. The company can be reached via phone at 972-2548-6555 or via email at [email protected] MarketBeat Community Rating for ANCHIANO THERAP/S (NASDAQ ANCN)Community Ranking: 2.5 out of 5 ( )Outperform Votes: 53 (Thanks for Voting!)Underperform Votes: 55 (Thanks for Voting!)Total Votes: 108MarketBeat's community ratings are surveys of what our community members think about ANCHIANO THERAP/S and other stocks. Vote "Outperform" if you believe ANCN will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ANCN will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 2/21/2020 by MarketBeat.com StaffFeatured Article: Which market index is the best?
